{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:46:50Z","timestamp":1792118810981,"version":"4.4.0"},"reference-count":56,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T00:00:00Z","timestamp":1372118400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0066243","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T21:18:23Z","timestamp":1372195103000},"page":"e66243","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":42,"title":["Triple Negative Breast Cancers Have a Reduced Expression of DNA Repair Genes"],"prefix":"10.1371","volume":"8","author":[{"given":"Enilze","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Ganzinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Andreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Bertoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Broggini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Zanoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letizia","family":"Bazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Foroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Damia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2013,6,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1634\/theoncologist.2011-S1-71","article-title":"Directed therapy of subtypes of triple-negative breast cancer","volume":"16","author":"LA Carey","year":"2011","journal-title":"Oncologist"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2011-S1-01","article-title":"Triple-negative breast cancer: an unmet medical need","volume":"16","author":"CA Hudis","year":"2011","journal-title":"Oncologist"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00432-010-0957-x","article-title":"Characteristics of triple-negative breast cancer","volume":"137","author":"TC de Ruijter","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/bcr2574","article-title":"Triple-negative breast cancer","volume":"12","author":"RD Chacon","year":"2010","journal-title":"Breast Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1634\/theoncologist.2011-S1-61","article-title":"Molecular stratification of triple-negative breast cancers","volume":"16","author":"CM Perou","year":"2011","journal-title":"Oncologist"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"CM Perou","year":"2000","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/ijc.23518","article-title":"How basal are triple-negative breast cancers?","volume":"123","author":"F Bertucci","year":"2008","journal-title":"Int J Cancer"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1158\/1078-0432.CCR-08-2132","article-title":"Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes","volume":"15","author":"EA Rakha","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/sj.onc.1209876","article-title":"Basal-like breast cancer and the BRCA1 phenotype","volume":"25","author":"NC Turner","year":"2006","journal-title":"Oncogene"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","article-title":"Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer","volume":"26","author":"DP Atchley","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1541-7786.MCR-05-0192","article-title":"The role of the BRCA1 tumor suppressor in DNA double-strand break repair","volume":"3","author":"J Zhang","year":"2005","journal-title":"Mol Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng953","article-title":"BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair","volume":"32","author":"AR Hartman","year":"2002","journal-title":"Nat Genet"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nrc1457","article-title":"Hallmarks of \u2018BRCAness\u2019 in sporadic cancers","volume":"4","author":"N Turner","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.onc.1210014","article-title":"BRCA1 dysfunction in sporadic basal-like breast cancer","volume":"26","author":"NC Turner","year":"2007","journal-title":"Oncogene"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/0008-5472.CAN-08-4016","article-title":"Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase","volume":"69","author":"E Alli","year":"2009","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, et al.. (2012) Methylation of O (6)-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat.","DOI":"10.1007\/s10549-011-1945-9"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/bjc.2011.518","article-title":"Absence of the DNA repair enzyme human 8-oxoguanine glycosylase is associated with an aggressive breast cancer phenotype","volume":"106","author":"P Karihtala","year":"2012","journal-title":"Br J Cancer"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, et al.. (2011) Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat [Epub ahead of print].","DOI":"10.1007\/s10549-011-1846-y"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/gcc.20366","article-title":"Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer","volume":"45","author":"A Bergamaschi","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-08-1791","article-title":"Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array","volume":"15","author":"F Andre","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/bcr2566","article-title":"Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms","volume":"12","author":"BP Rowe","year":"2010","journal-title":"Breast Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ijc.23551","article-title":"A sensitive test for the detection of specific DSB repair defects in primary cells from breast cancer specimens","volume":"123","author":"M Keimling","year":"2008","journal-title":"Int J Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-09-2758","article-title":"Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors","volume":"16","author":"A Mukhopadhyay","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/annonc\/mdq468","article-title":"Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy","volume":"22","author":"EH Lips","year":"2011","journal-title":"Ann Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CCO.0b013e328341ee38","article-title":"Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer","volume":"23","author":"SI Rothschild","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1200\/JCO.2009.27.5719","article-title":"Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer","volume":"28","author":"PA Konstantinopoulos","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PPO.0b013e318212f844","article-title":"Molecular predictors of response to chemotherapy in colorectal cancer","volume":"17","author":"R Dienstmann","year":"2011","journal-title":"Cancer J"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.2007.13.7083","article-title":"Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer","volume":"27","author":"D Generali","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kornegoor R, Verschuur-Maes AH, Buerger H, Hogenes MC, de Bruin PC, et al.. (2011) Molecular subtyping of male breast cancer by immunohistochemistry. Mod Pathol.","DOI":"10.1038\/modpathol.2011.174"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.ejca.2008.09.034","article-title":"What is triple-negative breast cancer?","volume":"44","author":"WJ Irvin Jr","year":"2008","journal-title":"Eur J Cancer"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s12282-008-0042-3","article-title":"Is triple negative a prognostic factor in breast cancer?","volume":"15","author":"R Nishimura","year":"2008","journal-title":"Breast Cancer"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"R Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1524-4741.2008.00622.x","article-title":"Impact of triple negative phenotype on breast cancer prognosis","volume":"14","author":"HG Kaplan","year":"2008","journal-title":"Breast J"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1471-2407-8-307","article-title":"The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer","volume":"8","author":"J Rhee","year":"2008","journal-title":"BMC Cancer"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","article-title":"The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes","volume":"13","author":"LA Carey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1200\/JCO.2008.18.1024","article-title":"Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial","volume":"27","author":"J Hugh","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref37","first-page":"255","article-title":"Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer","volume":"36","author":"S Wang","year":"2009","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e31818d839b","article-title":"Therapeutic strategies for triple-negative breast cancer","volume":"14","author":"AR Tan","year":"2008","journal-title":"Cancer J"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2174\/1389450111007011317","article-title":"Genetic instability influences drug response in cancer cells","volume":"11","author":"G Damia","year":"2010","journal-title":"Curr Drug Targets"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.ejca.2007.05.003","article-title":"Targeting DNA repair as a promising approach in cancer therapy","volume":"43","author":"G Damia","year":"2007","journal-title":"Eur J Cancer"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z","article-title":"Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents","volume":"66","author":"G Damia","year":"1996","journal-title":"Int J Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1101\/sqb.2005.70.012","article-title":"Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer","volume":"70","author":"AN Tutt","year":"2005","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1200\/JCO.2005.05.4171","article-title":"DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes","volume":"24","author":"RD Kennedy","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1158\/1541-7786.MCR-09-0149","article-title":"Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies","volume":"7","author":"H Willers","year":"2009","journal-title":"Mol Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ctrv.2007.07.001","article-title":"Current status of excision repair cross complementing-group 1 (ERCC1) in cancer","volume":"33","author":"L Gossage","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"21725","DOI":"10.1073\/pnas.0914772107","article-title":"Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer","volume":"107","author":"JJ Latimer","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"5796","DOI":"10.1158\/1078-0432.CCR-10-0292","article-title":"DNA repair protein biomarkers associated with time to recurrence in triple-negative breast cancer","volume":"16","author":"BM Alexander","year":"2010","journal-title":"Clin Cancer Res"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrc3088","article-title":"DNA interstrand crosslink repair and cancer","volume":"11","author":"AJ Deans","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1101\/gad.1955310","article-title":"Expanded roles of the Fanconi anemia pathway in preserving genomic stability","volume":"24","author":"Y Kee","year":"2010","journal-title":"Genes Dev"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"KA Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1378\/chest.127.3.978","article-title":"ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer","volume":"127","author":"GR Simon","year":"2005","journal-title":"Chest"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-11-0790","article-title":"Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC","volume":"17","author":"L Friboulet","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.4161\/cc.10.13.16398","article-title":"Unleashing Chk1 in cancer therapy","volume":"10","author":"L Carrassa","year":"2011","journal-title":"Cell Cycle"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1158\/0008-5472.CAN-06-3545","article-title":"The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor\/progesterone receptor\/HER-2 breast carcinomas","volume":"67","author":"L Verlinden","year":"2007","journal-title":"Cancer Res"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s10549-011-1441-2","article-title":"PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy","volume":"127","author":"P Domagala","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1177\/1947601910383418","article-title":"Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types","volume":"1","author":"V Ossovskaya","year":"2010","journal-title":"Genes Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0066243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T09:02:11Z","timestamp":1563267731000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0066243"}},"subtitle":[],"editor":[{"given":"Robert W.","family":"Sobol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,25]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0066243","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,25]]}}}